glp-1 smoking receptor agonists for cessation: a... : Annals of Medicine & Surgery GLP-1 was approved as a

Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T et al (2015) Comparison of the effects on glycaemic control and -cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)

GLP-1 treatment for diabetes and obesity Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Ozempic for diabetes and in Wegovy for obesity

Jr., Hendry, P.L., Sheikh, S., Jones, C.W., Punches, B.E., Swor, R.A., Gentile, N.T., Murty, V.P., Hudak, L.A., Pascual, J.L., Seamon, M.J., Harris, E., Chang, A.M., Pearson, C., Peak, D.A., Merchant, R.C., Domeier, R.M., Rathlev, N.K., O'Neil, B.J., Sergot, P., Sanchez, L.D., Bruce, S.E., Sheridan, J.F., Harte, S.E., Kessler, R.C., Koenen, K.C., McLean, S.A., Stevens, J.S., Calhoun, V.D., Ressler, K.J

The GLP-1R are expressed in tissues other than pancreatic islets 24 , as in hepatocytes, but studies suggest that certain actions of GLP-1 in hepatic glucose metabolism occur through mechanisms that are independent of GLP-1R, and no alternative route seems to have been fully elucidated 25

It just feels harder than it should

The standard pharmacokinetic rule is 4-5 half-lives for steady state